Tuberculosis Drug Discovery Symposium
Monday, October 6, 2008
Seattle, WA

This one-day symposium brought together international leaders in drug discovery with graduate students, post-docs and researchers in and around Seattle to stimulate discussion on the hurdles we face in TB drug discovery.  Our program focused on two areas: the biological keys to discovering faster therapies, including models of persistence and target identification/validation, and various approaches to early phase drug discovery, including whole-cell screens and structure-based drug design.(A printable copy of the poster is available here.)

Our program culminated in a plenary lecture given by Professor Douglas Young, Imperial College London, as part of the Washington Global Health Alliance Discovery Lecture Series.

Speakers included:

• Tom Alber, UC Berkeley

• Clifton Barry III, NIAID, NIH

• Gail Cassell, Eli Lilly and Company

• Stewart Cole, EPFL

• Thomas Dick, Novartis Institute for Tropical Diseases

• Deborah Hung, Broad Institute

• John Overington, BioFocus DPI

• Tanya Parish, Infectious Disease Research Institute

• Lalita Ramakrishnan, University of Washington

• Eric Rubin, Harvard University

• James Sacchettini, Texas A&M University

This event was sponsored by the Lilly TB Drug Discovery Initiative and the Washington Global Health Alliance Discovery Series.

This page was last updated October 15, 2008.

HOME | CONTACT US | SITEMAP | DONATE | POLICY

©2008 Seattle Biomedical Research Institute. All rights reserved.

SBRI is a 501(c)3 not-for-profit organization. info@sbri.org